Invesco LLC Decreases Stock Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

Invesco LLC decreased its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 47.7% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,472 shares of the company's stock after selling 1,343 shares during the quarter. Invesco LLC's holdings in Medpace were worth $449,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. SBI Securities Co. Ltd. bought a new position in shares of Medpace during the 4th quarter worth approximately $31,000. Jones Financial Companies Lllp boosted its holdings in Medpace by 2,750.0% during the fourth quarter. Jones Financial Companies Lllp now owns 114 shares of the company's stock worth $38,000 after buying an additional 110 shares in the last quarter. Lindbrook Capital LLC boosted its holdings in Medpace by 27.6% during the fourth quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock worth $45,000 after buying an additional 29 shares in the last quarter. Assetmark Inc. boosted its holdings in Medpace by 20.1% during the fourth quarter. Assetmark Inc. now owns 173 shares of the company's stock worth $57,000 after buying an additional 29 shares in the last quarter. Finally, Colonial Trust Co SC raised its position in Medpace by 150.0% during the fourth quarter. Colonial Trust Co SC now owns 175 shares of the company's stock worth $58,000 after acquiring an additional 105 shares during the period. Institutional investors own 77.98% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the stock. Robert W. Baird reduced their target price on shares of Medpace from $340.00 to $313.00 and set a "neutral" rating for the company in a research report on Wednesday, April 23rd. Leerink Partners started coverage on shares of Medpace in a research note on Monday, March 24th. They set a "market perform" rating and a $330.00 target price for the company. TD Cowen lowered shares of Medpace from a "buy" rating to a "hold" rating and lowered their price objective for the company from $370.00 to $328.00 in a research note on Monday, April 14th. Mizuho decreased their price target on shares of Medpace from $400.00 to $355.00 and set an "outperform" rating for the company in a research note on Wednesday, April 9th. Finally, Truist Financial lowered their price target on shares of Medpace from $333.00 to $300.00 and set a "hold" rating for the company in a report on Wednesday, April 23rd. Twelve research analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $344.82.

Insider Activity at Medpace

In other Medpace news, Director Fred B. Davenport, Jr. sold 1,712 shares of the business's stock in a transaction on Thursday, April 24th. The shares were sold at an average price of $301.82, for a total transaction of $516,715.84. Following the sale, the director now directly owns 2,998 shares in the company, valued at approximately $904,856.36. The trade was a 36.35% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 20.30% of the stock is currently owned by insiders.

Medpace Trading Up 1.3%

Shares of Medpace stock traded up $3.89 during trading on Friday, reaching $310.69. The company's stock had a trading volume of 677,983 shares, compared to its average volume of 373,382. The company has a 50-day moving average price of $300.94 and a two-hundred day moving average price of $320.24. The firm has a market cap of $8.93 billion, a PE ratio of 23.72, a P/E/G ratio of 5.54 and a beta of 1.47. Medpace Holdings, Inc. has a fifty-two week low of $250.05 and a fifty-two week high of $459.77.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its earnings results on Monday, April 21st. The company reported $3.67 EPS for the quarter, beating analysts' consensus estimates of $3.06 by $0.61. The business had revenue of $558.57 million for the quarter, compared to analysts' expectations of $528.38 million. Medpace had a net margin of 19.31% and a return on equity of 54.36%. During the same period in the previous year, the company posted $3.20 EPS. On average, analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.